Aegerion Pharma: (NASD: AEGR)

$61.57

-0.13 (-0.21%)

Volume 1,792,712

May 17 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		58.83 - 62.69
	
		52wk Low - High
		12.87 - 63.72
	
		Previous Close
		61.70
	
		Avg. Volume
		773,821
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		1.77 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.18
	
		PE (Forward)
		0.00
	
		Current Year Est.
		-2.36
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		91 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/16/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -2.36
                        
                            Current Quarter Estimate
                            -0.64
                        
                            Most Accurate Estimate
                            -0.64
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-07-2013
                        
                            EPS Last Year
                            -2.69
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutics to treat lipid disorders. Its products include Lomitapide and Implitapide. Lomitapide is a small molecule microsomal triglyceride transfer protein inhibitor, or MTP-I, that is used as an oral once-a-day treatment for patients with severe lipid disorders. Implitapide is used in the treatment of hypertriglyceridemia. Aegerion Pharmaceuticals, Inc. is headquartered in Bridgewater, New Jersey.     
Full AEGR Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
AEGR Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.64	-0.59	-2.36	0.12
Number of Estimates	6	5	7	7
Low Estimate	-0.79	-0.77	-2.81	-1.20
High Estimate	-0.55	-0.47	-2.05	NA
Year Ago EPS	-0.60	-0.59	-2.58	-2.36
EPS Growth	-6.67%	0.00%	8.58%	105.21%

More AEGR Estimates

Average Earnings Estimates for AEGR

EPS Growth for AEGR

Industry Analysis

Name	Symbol	Previous Close
AEGERION PHARMA	AEGR	61.57
AETERNA ZENTARS	AEZS	2.10
ANIKA THERAPEUT	ANIK	14.40
GENTIUM SPA-ADR	GENT	8.87
AASTROM BIOSCI	ASTM	0.57
ACHILLION PHARM	ACHN	7.77
ADDEX THERA LTD	ADDXF	6.94
AFFYMAX INC	AFFY	1.33
ALEXION PHARMA	ALXN	102.90
ALKERMES INC	ALKS	31.69

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Loss at Aegerion Narrower Than Expected

May 03, 2013

Aegerion Incurs Wider Loss

Mar 07, 2013

Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals

Jan 31, 2013

US Nod for ISIS/Sanofi's Kynamro

Jan 30, 2013

Aegerion Prices Stock Offering

Jan 14, 2013

Aegerion to Raise Funds

Jan 11, 2013

Aegerion Upbeat About 2013

Jan 08, 2013

FDA Approves Aegerion's Juxtapid

Dec 26, 2012

More AEGR Zacks Commentary

Financials

EPS TTM	-2.69
Sales	NA
Net Income	-69
Price/Earnings	NA
Price/Book	13.99
Price/Cash Flow	NA
Price/Sales	NA

More AEGR Financials

News

3 Humongous Health-Care Stocks This Week - TheMotleyFool

May 18, 2013

EGLE, TSLA, ARUN Added to Watch List at GSR - Accesswire-Tnw

May 17, 2013

Market Maker Surveillance Report. SBSA, EGLE, AEGR, ANW, SINO, DQ, Winning Stocks With Lowest Price Friction For Thursday, May 16th 2013 - M2

May 17, 2013

3 Stocks Near 52-Week Highs Worth Selling - TheMotleyFool

May 16, 2013

Hedge Funds and Insiders are Buying 8 Small Caps - Kapitall

May 16, 2013

Market Wrap for Thursday, May 16: A Small Pullback For U.S. Stocks as Economic Data Disappoints - Benzinga

May 16, 2013

Mid-Afternoon Market Update: Optimer Falls as Halozyme Rockets Upwards - Benzinga

May 16, 2013

Mid-Day Market Update: US Stocks Fluctuate, Cisco Systems Up on Better-than-Expected Earnings - Benzinga

May 16, 2013

See All News Stories on AEGR

Broker Recommendations

Current ABR	1.09
ABR (Last Week)	1.09
# of recs in ABR	11
Average Target Price	55.22
Industry Rank by ABR	91 out of 265
Rank in Industry	36 out of 155

More AEGR Broker Recommendations

Day Low - High	58.83 - 62.69
52wk Low - High	12.87 - 63.72
Previous Close	61.70
Avg. Volume	773,821
Industry	MED-BIOMED/GENE
Market Cap	1.77 B
Div - Yield	0.00 - 0.00
Beta	0.18
PE (Forward)	0.00
Current Year Est.	-2.36
Quarterly Earnings ESP	0.00%

PE (Forward)	NA
PEG Ratio	NA
Current Year Est.	-2.36
Current Quarter Estimate	-0.64
Most Accurate Estimate	-0.64
Earnings ESP	0.00%
Next Earnings Report Date	08-07-2013
EPS Last Year	-2.69
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

Aegerion Pharma: (NASD: AEGR)

$61.57

-0.13 (-0.21%)

Volume 1,792,712

May 17 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-BIOMED/GENE

Zacks Commentary

Financials

News

Broker Recommendations